NCT06788639View on ClinicalTrials.gov

A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

June 30, 2044

Study Completion Date

June 30, 2044

Conditions
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Interventions
BIOLOGICAL

Lisocabtagene maraleucel

According to the United States Prescribing Information

Trial Locations (1)

53226

RECRUITING

Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee

All Listed Sponsors
lead

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

INDUSTRY